USTR "intimidating" Brazil over HIV/AIDS drugs

13 May 2001

US President George W Bush should stop the US Trade Representative from"trying to intimidate Brazil from providing cheap generic AIDS drugs," says Raymond Offenheiser, president of the Oxfam America aid agency. "Brazil has proven you can treat very poor people successfully, their program is cited for excellence by the World Bank, the United Nations and medical professionals, and the USA is trying to shut it down," he noted.

Last month, the UN Human Rights Commission unanimously approved a Brazilian resolution which stated that access to medicines is a human right. Only the USA abstained from the vote.

Meantime, Paulo Teixeira, director of the Brazilian government's AIDS program, is to present a three-point plan at next month's UN AIDS summit in New York (Marketletter May 14) which will call for differential drug pricing based on the purchasing country's socio economic conditions, safeguards to protect individual countries' patent laws and the establishment of a global fund to tackle AIDS, reports the Gazeta Mercantil.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight